Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Argus Health
Covington
Medtronic
Johnson and Johnson
Baxter
UBS
Deloitte
Harvard Business School
Citi

Generated: August 20, 2017

DrugPatentWatch Database Preview

VALTREX Drug Profile

« Back to Dashboard

What is the patent landscape for Valtrex, and when can generic versions of Valtrex launch?

Valtrex is a drug marketed by Glaxosmithkline and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and two patent family members in forty-five countries.

The generic ingredient in VALTREX is valacyclovir hydrochloride. There are twenty-two drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the valacyclovir hydrochloride profile page.

Summary for Tradename: VALTREX

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list7
Bulk Api Vendors: see list46
Clinical Trials: see list47
Patent Applications: see list4,305
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:VALTREX at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline
VALTREX
valacyclovir hydrochloride
TABLET;ORAL020487-002Jun 23, 1995ABRXYesYes► Subscribe► Subscribe ► Subscribe
Glaxosmithkline
VALTREX
valacyclovir hydrochloride
TABLET;ORAL020487-001Jun 23, 1995ABRXYesNo► Subscribe► Subscribe ► Subscribe
Glaxosmithkline
VALTREX
valacyclovir hydrochloride
TABLET;ORAL020487-002Jun 23, 1995ABRXYesYes► Subscribe► Subscribe ► Subscribe
Glaxosmithkline
VALTREX
valacyclovir hydrochloride
TABLET;ORAL020487-001Jun 23, 1995ABRXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: VALTREX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline
VALTREX
valacyclovir hydrochloride
TABLET;ORAL020487-002Jun 23, 1995► Subscribe► Subscribe
Glaxosmithkline
VALTREX
valacyclovir hydrochloride
TABLET;ORAL020487-001Jun 23, 1995► Subscribe► Subscribe
Glaxosmithkline
VALTREX
valacyclovir hydrochloride
TABLET;ORAL020487-002Jun 23, 1995► Subscribe► Subscribe
Glaxosmithkline
VALTREX
valacyclovir hydrochloride
TABLET;ORAL020487-001Jun 23, 1995► Subscribe► Subscribe
Glaxosmithkline
VALTREX
valacyclovir hydrochloride
TABLET;ORAL020487-001Jun 23, 1995► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VALTREX

Country Document Number Estimated Expiration
European Patent Office0804436► Subscribe
India182468► Subscribe
Norway315558► Subscribe
Iceland2268► Subscribe
New Zealand298846► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Cipla
Argus Health
Daiichi Sankyo
Moodys
Novartis
McKinsey
QuintilesIMS
Harvard Business School
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot